Identification of novel Kv1.3 channel dependent mechanisms in microglial activation
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Microglial Cell
DISEASE(S): Alzheimer's Disease
SUBMITTER: 
Eric Dammer
LAB HEAD: Nicholas T. Seyfried
PROVIDER: PXD006753 | Pride | 2018-10-24
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Rangaraju-BV2-MaxQuant_TXT_OUTPUT.zip | Other | |||
| UP000000589_10090_mouseUNIPROTsep15withegfp.fasta | Fasta | |||
| sr_04.raw | Raw | |||
| sr_05.raw | Raw | |||
| sr_06.raw | Raw |
Items per page: 5 1 - 5 of 20 |
Publications
A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation.
Rangaraju Srikant S Raza Syed Ali SA Pennati Andrea A Deng Qiudong Q Dammer Eric B EB Duong Duc D Pennington Michael W MW Tansey Malu G MG Lah James J JJ Betarbet Ranjita R Seyfried Nicholas T NT Levey Allan I AI
Journal of neuroinflammation 20170626 1
<h4>Background</h4>Kv1.3 potassium channels regulate microglial functions and are overexpressed in neuroinflammatory diseases. Kv1.3 blockade may selectively inhibit pro-inflammatory microglia in neurological diseases but the molecular and cellular mechanisms regulated by Kv1.3 channels are poorly defined.<h4>Methods</h4>We performed immunoblotting and flow cytometry to confirm Kv1.3 channel upregulation in lipopolysaccharide (LPS)-activated BV2 microglia and in brain mononuclear phagocytes fres ...[more]
Similar Datasets
Project description:Kv1.3, a voltage-gated potassium channel, is a therapeutic target in various neuropathological conditions. In rodent models, Kv1.3 inhibitors have been shown to inhibit disease-induced neuroinflammation. However, the cellular mechanisms of disease-modification by Kv1.3 blockers and the signaling pathways regulated by Kv1.3 and are unclear. In this -study, we aim to delineate the major protective mechanisms of Kv1.3 blockade in Alzheimer’s disease (AD) pathology by investigating the brain-derived bulk and single nuclear transcriptomes (snRNAseq) and bulk proteomes, along with neurobehavioral and pathological changes in 5xFAD mice. Following 3 months of Kv1.3 blockade via either small molecule PAP-1 or ShK-223 peptide, we observed Ab plaque reduction with both drugs and improved behavior with PAP-1. snRNAseq of brain nuclei identified neuronal and glial populations with expected AD-related changes in microglia. Pseudo-bulk analyses showed that PAP-1 disproportionately impacted oligodendrocytes and microglia while ShK-223 had more pronounced effects on glutamatergic neurons. PAP-1 also increased expression of myelination genes in oligodendrocytes and synaptic genes in neurons, with distinct effects on excitatory and inhibitory neurons. Cell-cell communication analyses suggested that PAP-1 increased crosstalk between neurons and astrocytes with endothelial cells. Bulk brain transcriptomics and proteomics with PAP-1 showed increased levels of synaptic and cognitive resilience-associated proteins while decreasing glial activation and interferon (IFN) responsive genes/proteins. PAP-1 also decreased STAT1 phosphorylation in the 5xFAD brain. To gain further mechanistic insight into Kv1.3's role in interferon signaling in microglia, we confirmed physical interactions between Kv1.3 and STAT1 and STAT3 in BV2 microglia overexpressing Kv1.3. We also found that Kv1.3 blockade (PAP-1) specifically reduced type 2 IFN but not type 1 IFN-induced phosphorylation of STAT1/3, a finding with further validated in another microglial cell line as well as in primary microglia derived from wild-type or Kv1.3-knockout mice. Lastly, we identified novel proteomic changes occurring in cerebrospinal fluid that reflect disease-modification by Kv1.3 blockers. This study reveals cell type-specific effects of Kv1.3 blockers in AD pathology that correspond with reduced neuropathology and neuroinflammation, augmentation of resilience pathways and neuro-vascular coupling and translationally relevant biofluid biomarkers of therapeutic effect. We also provide novel mechanistic insights into functional coupling between Kv1.3 channels and type-2 IFN signaling pathways in microglia.
2026-07-13 | PXD071599 | Pride
Project description:Potassium channels regulate membrane potential, calcium flux, cellular activation and effector functions of adaptive and innate immune cells. The voltage-activated Kv1.3 channel is an important regulator of T cell-mediated autoimmunity and microglia-mediated neuroinflammation. Kv1.3 channels, via protein-protein interactions, are localized with key immune proteins and pathways, allowing functional coupling between K+ efflux and immune mechanisms. To gain insights into proteins and pathways that interact with Kv1.3 channels, we applied a proximity-labeling proteomics approach to characterize protein interactors of the Kv1.3 channel in activated T cells. Biotin ligase TurboID was fused to either N or C termini of Kv1.3, stably expressed in Jurkat T cells and biotinylated proteins in proximity to Kv1.3 were enriched and quantified by mass spectrometry. We identified over 1,800 Kv1.3 interactors including known interactors (beta-integrins, Bax, Stat1) although majority were novel. We found that the N-terminus of Kv1.3 preferentially interacts with protein synthesis and protein trafficking machinery, while the C-terminus interacts with immune signaling and cell junction proteins. In contrast to Kv1.3 interactors in microglia, T cell Kv1.3 interactors included 182 cell surface, T cell receptor complex, mitochondrial, calcium sand cytokine-mediated signaling pathway and lymphocyte migration proteins. 178 Kv1.3 interactors in T cells also represent genetic risk factors of T cell-mediated autoimmunity, including STIM1, which was further validated using co-immunoprecipitation. Our studies reveal novel proteins and molecular pathways that interact with Kv1.3 channels in adaptive (T cell) and innate immune (microglia), providing a foundation for how Kv1.3 channels may regulate immune mechanisms in autoimmune and neurological diseases.
2026-03-23 | PXD059644 | Pride
Project description:Abstract Inhibition of voltage-gated potassium channel Kv1.3 is a therapeutic strategy to curb microglia-mediated neuroinflammation in neurodegeneration, although the cellular and signaling mechanisms of disease-modification by Kv1.3 blockers are unclear. In this study, we delineate protective mechanisms of Kv1.3 blockade in a mouse model of Alzheimer's disease (AD) pathology using comprehensive transcriptomics and proteomics profiling of brain, corresponding with neuropathological effects of two translationally relevant Kv1.3 blockers, namely small molecule PAP-1 and peptide ShK-223. Following 3 months of treatment, both molecules reduced Ab plaque burden. Single nuclear RNA seq (snRNA seq) of brain nuclei showed that PAP-1 disproportionately impacted oligodendrocytes and microglia and increased crosstalk between neurons and astrocytes with endothelial cells. In contrast, ShK-223 had pronounced effects on glutamatergic neurons and astrocytes. Both blockers increased expression of myelination genes in oligodendrocytes and synaptic genes in neurons. Neuroprotective effects of PAP-1 were further confirmed by bulk brain transcriptomics and proteomics whereby PAP-1 increased levels of synaptic, cognitive resilience and mitochondrial proteins, while decreasing glial and immune pathways including STAT1/3 phosphorylation. Using proximity labeling and co-immunoprecipitation, we found that Kv1.3 interacts with STAT1/3 in microglia. Using microglial cell lines and primary microglia, we discovered a preferential functional coupling between Kv1.3 and type 2 but not type 1 IFN signaling. Brain-level disease modification by Kv1.3 blockade was reflected in the cerebrospinal fluid (CSF) via reduced levels of neurofilament-light (NEFL) and resilience protein RPH3A, both of which are increased in human AD CSF. Together, this study demonstrates functional links between Kv1.3 channels and type 2 IFN signaling and reveals distinct cellular effects of Kv1.3 blockers in AD pathology that correspond with reduced neuropathology and neuroinflammation, augmentation of resilience and neuro-vascular pathways, along with biomarkers of therapeutic effect.
2026-07-15 | GSE338689 | GEO
Project description:Microglia are resident immune cells of the brain and regulate its inflammatory state. In neurodegenerative diseases, microglia transition from a homeostatic state to a state referred to as disease associated microglia (DAM). DAM express higher levels of proinflammatory signaling molecules, like STAT1 and TLR2, and show transitions in mitochondrial activity toward a more glycolytic response. Inhibition of Kv1.3 decreases the proinflammatory signature of DAM, though how Kv1.3 influences the response is unknown. Our goal was to establish the potential proteins interacting with Kv1.3 during transition to DAM. We utilized TurboID, a biotin ligase, fused to Kv1.3 to evaluate the potential interacting proteins with Kv1.3 via mass spectrometry in BV-2 microglia following TLR4-mediated activation. Electrophysiology, western blotting, and flow cytometry were used to evaluate Kv1.3 channel presence and TurboID biotinylation activity. We hypothesized that Kv1.3 contains domain-specific interactors that vary during a TLR4-induced inflammatory response, some of which are dependent on the PDZ-binding domain on the C-terminus. We determined that the N-terminus of Kv1.3 is responsible for trafficking Kv1.3 to the cell surface and mitochondria (e.g. NUNDC, TIMM50). Whereas, the C-terminus interacts with immune signaling proteins in an LPS-induced inflammatory response (e.g. STAT1, TLR2, and C3). There are 70 proteins that rely on the C-terminal PDZ-binding domain to interact with Kv1.3 (e.g. ND3, Snx3, and Sun1). Overall, we highlight that the Kv1.3 potassium channel functions beyond conducting the outward flux of potassium ions in an inflammatory context and that KV1.3 modulates activity of key immune signaling proteins, such as STAT1 and C3
2024-05-06 | PXD049433 | Pride
Project description:Kv1.3, a voltage-gated potassium channel, is a therapeutic target in various neuropathological conditions. In rodent models, Kv1.3 inhibitors have been shown to inhibit disease-induced neuroinflammation. However, the cellular mechanisms of disease-modification by Kv1.3 blockers and the signaling pathways regulated by Kv1.3 and are unclear. In this -study, we aim to delineate the major protective mechanisms of Kv1.3 blockade in Alzheimer’s disease (AD) pathology by investigating the brain-derived bulk and single nuclear transcriptomes (snRNAseq) and bulk proteomes, along with neurobehavioral and pathological changes in 5xFAD mice. Following 3 months of Kv1.3 blockade via either small molecule PAP-1 or ShK-223 peptide, we observed Ab plaque reduction with both drugs and improved behavior with PAP-1. snRNAseq of brain nuclei identified neuronal and glial populations with expected AD-related changes in microglia. Pseudo-bulk analyses showed that PAP-1 disproportionately impacted oligodendrocytes and microglia while ShK-223 had more pronounced effects on glutamatergic neurons. PAP-1 also increased expression of myelination genes in oligodendrocytes and synaptic genes in neurons, with distinct effects on excitatory and inhibitory neurons. Cell-cell communication analyses suggested that PAP-1 increased crosstalk between neurons and astrocytes with endothelial cells. Bulk brain transcriptomics and proteomics with PAP-1 showed increased levels of synaptic and cognitive resilience-associated proteins while decreasing glial activation and interferon (IFN) responsive genes/proteins. PAP-1 also decreased STAT1 phosphorylation in the 5xFAD brain. To gain further mechanistic insight into Kv1.3's role in interferon signaling in microglia, we confirmed physical interactions between Kv1.3 and STAT1 and STAT3 in BV2 microglia overexpressing Kv1.3. We also found that Kv1.3 blockade (PAP-1) specifically reduced type 2 IFN but not type 1 IFN-induced phosphorylation of STAT1/3, a finding with further validated in another microglial cell line as well as in primary microglia derived from wild-type or Kv1.3-knockout mice. Lastly, we identified novel proteomic changes occurring in cerebrospinal fluid that reflect disease-modification by Kv1.3 blockers. This study reveals cell type-specific effects of Kv1.3 blockers in AD pathology that correspond with reduced neuropathology and neuroinflammation, augmentation of resilience pathways and neuro-vascular coupling and translationally relevant biofluid biomarkers of therapeutic effect. We also provide novel mechanistic insights into functional coupling between Kv1.3 channels and type-2 IFN signaling pathways in microglia.
2026-07-13 | PXD072055 | Pride
Project description:Microglia and neuroinflammation play an important role in the development and progression of Alzheimer’s disease (AD). Inositol polyphosphate-5-phosphatase D (INPP5D) is a myeloid-expressed gene genetically-associated with AD. Through unbiased analyses of RNA and protein profiles in INPP5D-disrupted iPSC-derived human microglia, we find that reduction in INPP5D activity is associated with molecular profiles consistent with disrupted autophagy and inflammasome activation. These findings are validated through targeted pharmacological experiments which demonstrate that reduced INPP5D activity induces the formation of the NLRP3 inflammasome, cleavage of CASP1, and secretion of IL-1 and IL-18. Further, in-depth analyses of human brain tissue across hundreds of individuals using a multi-analytic approach provides evidence that a reduction in function of INPP5D in microglia results in inflammasome activation in AD. These findings provide insights into the molecular mechanisms underlying microglia-mediated processes in AD and highlight the inflammasome as a potential therapeutic target for modulating INPP5D-mediated vulnerability to AD.
2024-01-26 | PXD046040 | Pride
Project description:Alpha-synuclein aggregates (αSynAgg) are pathological hallmarks of Parkinson’s disease (PD) that induce microglial activation and immune-mediated neurotoxicity, although the molecular mechanisms of αSynAgg-induced immune activation are poorly defined. We used mass spectrometry to define proteomic changes induced by αSynAgg using in-vitro mouse microglia and an in-vivo fly (Drosophila melanogaster) model with neuron-specific αSyn overexpression. In mouse microglia, αSynAgg induced robust pro-inflammatory activation (increased expression of 864 genes including Irg1, Ifit1 and Pyhin) and increased nuclear proteins involved in RNA synthesis, splicing and anti-viral defense mechanisms. Conversely, αSynAgg decreased expression of 530 proteins (including Cdc123, Sod1 and Grn), which were predominantly cytosolic and involved in antigen presentation as well as metabolic, proteosomal and lysosomal mechanisms. Pathway analyses and confirmatory in -vitro studies suggested that αSynAgg partly mediates its effects via Stat3 activation. 26 proteins differentially-expressed by αSynAgg were also identified as PD risk genes in genome-wide association studies (upregulated: Brd2, Clk1, Siglec1; down-regulated: Memo1, Arhgap18, Fyn and PGgrn/Grn). We then validated progranulin (PGrn/Grn) as a lysosomal PD-associated protein that is decreased in striatal and nigral microglia in post-mortem PD brain compared to non-disease controls, congruent with our in -vitro findings.
2020-01-24 | PXD013691 | Pride
Project description:Increased expression of the voltage-gated potassium channel Kv1.3 in activated microglia and the subsequent release of pro-inflammatory mediators are closely associated with the progression of Alzheimer’s disease (AD). Studies have demonstrated that blockade of microglial Kv1.3 has the potential to improve cognitive function in mouse model of familial AD. Our laboratory has developed a potent and highly selective Kv1.3 peptide blocker, HsTX1[R14A]. This study aims to demonstrate the efficacy of HsTX1[R14A] in a mouse model of sporadic AD, the senescence accelerated mouse (SAMP8). SAMP8 mice were subcutaneously dosed with either PBS or HsTX1[R14A] (1 mg/kg) every other day from 4 months old for 8 weeks. We then performed gene expression profiling analysis using data obtained from RNA-seq of the brains collected from these mice at the conclusion of treatment.
2023-05-11 | GSE221352 | GEO
Project description:Microglia become activated by disturbances in the homeostasis of their local microenvironment. While there are varying degrees of microglia activation, a pro-inflammatory reactive state induced by exposure to stimuli like LPS and IFN-γ. In this study, we identified a total of 5497 proteins in whole cell proteome and 4938 proteins for secretome of activated BV-2 mouse microglia cell line with LPS or IFN-γ using improved shotgun proteomic approach. From the differentially expressed proteins in stimulated microglia, we were able to classify pathways related immune-inflammatory response or metabolism. Moreover, we performed longitudinal quantification of secreted proteins during the detrimental activation of microglia which releases neurotoxic molecules mediated neuronal cell loss in the brain region.
2017-08-09 | PXD006558 | Pride
Project description:Metabolic reprogramming is a hallmark of the immune cells in response to inflammatory stimuli. This metabolic process involves a switch from oxidative phosphorylation (OXPHOS)to glycolysis, or alterations in other metabolic pathways. However, most of the experimental findings have been acquired in murine immune cells and little is known about the metabolic reprogramming of human microglia. In this study, we investigated the transcriptomic and metabolic profiles of mouse and iPSC-derived human microglia challenged with the TLR4 agonist LPS. We found that both species displayed a metabolic shift and an overall increased glycolytic gene signature in response to LPS treatment. The metabolic reprogramming was characterized by the upregulation of hexokinases in mouse microglia and phosphofructokinases in human microglia. This study provides the first direct comparison of energy metabolism between mouse and human microglia, highlighting the species-specific pathways involved in immunometabolism and the importance of considering these differences in translational research.
2023-09-02 | PXD043836 | Pride